The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers
LOS ANGELES and ATLANTA, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc. (Nasdaq: GOVX), produced a robust neutralizing antibody and T cell (an immune cell) response against SARS-CoV-2 with no significant side effects in a Phase 1 clinical trial led by John Zaia, M.D., Aaron D. Miller and Edith Miller Chair for Gene Therapy, according to a study published today in The Lancet Microbe.
Read more at globenewswire.com